Torna al Registre Simple

 

HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01

dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorSIENA, SALVATORE
dc.contributor.authorRaghav, Kanwal
dc.contributor.authorYamaguchi, Kensei
dc.contributor.authorNishina, Tomohiro
dc.contributor.authorMasuishi, Toshiki
dc.contributor.authorElez, Elena
dc.date.accessioned2025-01-15T07:49:58Z
dc.date.available2025-01-15T07:49:58Z
dc.date.issued2024-11-25
dc.identifier.citationSiena S, Raghav K, Masuishi T, Yamaguchi K, Nishina T, Elez E, et al. HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01. Nat Commun. 2024 Nov 25;15:10213.
dc.identifier.issn2041-1723
dc.identifier.urihttps://hdl.handle.net/11351/12413
dc.descriptionBiomarcadors; Resultats clínics; Càncer colorectal metastàtic
dc.descriptionBiomarcadores; Resultados clínicos; Cáncer colorrectal metastásico
dc.language.isoeng
dc.publisherNature Portfolio
dc.relation.ispartofseriesNature Communications;15
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectAvaluació de resultats (Assistència sanitària)
dc.subjectMedicaments antineoplàstics - Ús terapèutic
dc.subjectImmunoteràpia
dc.subjectRecte - Càncer - Tractament
dc.subjectCòlon - Càncer - Tractament
dc.subjectMarcadors tumorals
dc.subjectMetàstasi
dc.subject.meshAntineoplastic Agents, Immunological
dc.subject.meshBiomarkers, Tumor
dc.subject.meshColorectal Neoplasms
dc.subject.mesh/drug therapy
dc.subject.meshNeoplasm Metastasis
dc.subject.meshTreatment Outcome
dc.titleHER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1038/s41467-024-53223-3
dc.subject.decsinmunoterapia antineoplásica
dc.subject.decsmarcadores tumorales
dc.subject.decsneoplasias colorrectales
dc.subject.decs/farmacoterapia
dc.subject.decsmetástasis neoplásica
dc.subject.decsresultado del tratamiento
dc.relation.publishversionhttps://doi.org/10.1038/s41467-024-53223-3
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Siena S] Department of Oncology and Hemato-Oncology, Università degli Studi di Milano and Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy. [Raghav K] Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. [Masuishi T] Department of Clinical Oncology, Aichi Cancer Center Hospital, Aichi, Japan. [Yamaguchi K] The Cancer Institute Hospital of JFCR, Tokyo, Japan. [Nishina T] National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan. [Elez E] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.identifier.pmid39587050
dc.identifier.wos001364059600021
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Portada del document
Name:
her2-related-biomarkers-predic ...
Grandària:
962.4Kb
Format:
PDF
Description:
HER2-related biomarkers predict ...
Visualitza

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple